A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Back to Current Clinical Trials

Protocol

ALLR18: A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Diseases

Leukemias / Lymphomas : Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

Description

Participants who have B-cell acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL) that has either come back after treatment, or did not go into remission with treatment are invited to take part in this phase II study. When ALL or NHL does not go into remission or if it comes back, it can be difficult to treat. In this study, all patients will get chemotherapy and specially selected cells (natural-killer cells) from the blood of a donor (usually a parent or close relative). Some patients may also get a stem cell transplant depending on the characteristics of their disease.

Objectives

To learn how many participants treated on this study will achieve remission (no signs of leukemia or lymphoma) and how many will still be in remission 3 years after enrolling on this study.
To find out how many participants treated on this study will have negative MRD (minimal residual disease) after induction, compared to a previous St. Jude study.
To learn more about biology and genetics of lymphoblastic leukemia and lymphoma by studying blood and bone marrow specimens from people enrolled on this study for research.

Eligibility criteria, among others, include:

Participant is < 22 years of age at time of enrollment (e.g., participant eligible until 22nd birthday).
Participant with ALL or NHL in first remission is off immune suppression for > 2 weeks
Participant does not have HIV infection
Participant does not have hepatitis B infection
Participant with lymphoma meets one of the following:
- In first relapse, or
- Refractory to one two courses of frontline induction therapy with measurable disease.

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Contact

Deepa Bhojwani, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article